TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06457425
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For patients with platelet counts between 100×10\^9/L and 200×10\^9/L, the recommended starting dose is 15 mg twice daily (bid). For patients with platelet counts \>200×10\^9/L, the recommended starting dose is 20 mg bid. For patients with platelet counts between 50×10\^9/L and \<100×10\^9/L, the recommended maximum starting dose is 5 mg bid.
Study: NCT04544293
Drug: Molgramostim
Normalized name: molgramostim
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molgramostim 300 µg nebulizer solution
Study: NCT05426486
Drug: Pyrotinib maleate
Normalized name: maleate
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR/HER2 dual inhibitor
Study: NCT05426486
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-Her2 monoclonal antibody
Study: NCT05426486
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-HER2 monoclonal antibody
Study: NCT05426486
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytotoxic chemotherapy
Study: NCT05426486
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytotoxic chemotherapy
Study: NCT06598462
Drug: Solrikitug Low Dose
Normalized name: ethinyl estradiol
DrugBank: Solrikitug (DB19301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solrikitug low dose subcutaneous injection
Study: NCT06598462
Drug: Solrikitug Mid Dose
Normalized name: Solrikitug
DrugBank: Solrikitug (DB19301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solrikitug mid dose subcutaneous injection
Study: NCT06598462
Drug: Solrikitug High Dose
Normalized name: high-density polyethylene
DrugBank: Solrikitug (DB19301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solrikitug high dose subcutaneous injection
Study: NCT05230368
Drug: Decitabine cycle 1
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine administration (5mg/m²) at days 1, 2, 3
Study: NCT05230368
Drug: Romidepsin cycle 1
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin administration (5mg/m²) at days 4, 11, 18
Study: NCT05230368
Drug: Decitabine cycle 2
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine administration (5mg/m²) at days 35, 36, 37
Study: NCT05230368
Drug: Romidepsin cycle 2
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin administration (5mg/m²) at days 38, 45, 52
Study: NCT05230368
Drug: Decitabine cycle 3
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine administration (5mg/m²) at days 70, 71, 72
Study: NCT05230368
Drug: Romidepsin cycle 3
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin administration (5mg/m²) at days 73, 80, 87
Study: NCT05230368
Drug: Decitabine cycle 4
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine administration (5mg/m²) at days 105, 106, 107
Study: NCT05230368
Drug: Romidepsin cycle 4
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin administration (5mg/m²) at days 108, 115, 122
Study: NCT05184062
Drug: 600 mg AZD7442 IV
Normalized name: AZD7442
DrugBank: AZD7442 (DB15787)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive co-administration of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by a single IV infusion.
Study: NCT06068881
Drug: Tazverik (Tazemetostat)
Normalized name: Tazverik
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Tablet
Study: NCT05797831
Drug: Navtemadlin
Normalized name: Navtemadlin
DrugBank: Navtemadlin (DB15299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navtemadlin is an experimental MDM2 anticancer drug taken by mouth
Study: NCT05797831
Drug: Navtemadlin Placebo
DrugBank: Navtemadlin (DB15299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth
Study: NCT06678269
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dose escalation portion of the study, a 3+3 design will be used. Once the MTD of Abemaciclib is reached, the phase Ib expansion portion will enroll up to 10 additional patients also requiring palliation to bone metastases
Study: NCT06665438
Drug: Normal Saline (Placebo)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the 18 ml of normal saline will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure
Study: NCT06665438
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the 18ml 0.25% bupivacaine. will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure
Study: NCT06665438
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine 1 μg/kg will injected intra articular in the knee joint by the surgeon through the arthroscope after completing the procedure.
Study: NCT04791319
Drug: Bermekimab
Normalized name: Bermekimab
DrugBank: Bermekimab (DB14947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bermekimab will be administered subcutaneously.
Study: NCT04791319
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dupilumab will be administered subcutaneously.
Study: NCT04891770
Drug: Tenofovir Alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as film-coated oral tablets
Study: NCT04891770
Drug: VIR-2218
Normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a sub-cutaneous (SC) injection
Study: NCT04891770
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT04891770
Drug: Selgantolimod
Normalized name: Selgantolimod
DrugBank: Selgantolimod (DB16324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as film-coated oral tablets
Study: NCT04959240
Drug: Velmanase Alfa
Normalized name: Velmanase alfa
DrugBank: Velmanase alfa (DB12374)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04919499
Drug: BI 765128
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 765128
Study: NCT06697431
Drug: Anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients who fulfill the eligibility criteria a will be randomized 1:1 to receive either~1. IVIG 2g/kg administered in 10-12 hours as per local standard of care (standard treatment) OR~2. Anakinra 2mg/kg intravenously, max 100 mg/dose 4 times/day (investigational treatment)~Patients showing fever, between 36 hours and 72 hours from the end of first line treatment will be considered failures. Failures from the investigational treatment arm will receive a dose of IVIG and they will drop from the study.~Children who remained afebrile between the 36th and 72nd hour will be considered as responders, and they will proceed into the study.~Patients in the standard treatment arm will continue ancillary treatment and follow-up .~Patients in the investigational treatment arm will enter the tapering phase.
Study: NCT06696105
Drug: Resin infiltration
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icon® resin infiltration (DMG America, Englewood, NJ, US) technique utilizes light-cured hydrophilic and low viscosity resins that can permeate WSL subsurface micropores. Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release . Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization.
Study: NCT06696105
Drug: Vanish XT varnish (resin modified glass ionomer restoration)
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin modified glass ionomer cement includes Fluoroaluminosilicate glass, which facilitates the interaction of fluoride with the enamel surface resulting in an instant release. Concurrently, the predominant glass matrix serves as source of fluoride for the purpose of continuous release, hypothesized to facilitate remineralization.
Study: NCT06085963
Drug: Nacl
Normalized name: NaCl
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium chloride solution 9mg/ml
Study: NCT02137525
Drug: Morphine 6 mg
Normalized name: apomorphine 6 MG
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion - delivering morphine 6 mg
Study: NCT06496217
Drug: MBX 2109
Normalized name: MBX-2109
DrugBank: MBX-2109 (DB18658)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Subjects with mild renal impairment (eGFR ≥ 60 and \< 90 mL/min)
Study: NCT06496217
Drug: MBX 2109
Normalized name: MBX-2109
DrugBank: MBX-2109 (DB18658)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Subjects with moderate renal impairment (eGFR ≥ 30 and \< 60 mL/min)
Study: NCT06496217
Drug: MBX 2109
Normalized name: MBX-2109
DrugBank: MBX-2109 (DB18658)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: Subjects with severe renal impairment (eGFR \< 30 mL/min), or kidney failure and not receiving dialysis
Study: NCT06496217
Drug: MBX 2109
Normalized name: MBX-2109
DrugBank: MBX-2109 (DB18658)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4: Matched healthy subjects with normal renal function (eGFR ≥ 90 mL/min)
Study: NCT04987762
Drug: Adhansia XR
Normalized name: Adhansia XR
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate extended-release capsules taken once daily (12.5 mg, 25 mg, 35 mg, 45 mg, 55 mg, and 70 mg)
Study: NCT05031546
Drug: Difelikefalin
Normalized name: DIFELIKEFALIN
DrugBank: Difelikefalin (DB11938)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Difelikefalin 0.5 mcg/kg administered after each dialysis session (3 times/week)
Study: NCT06056687
Drug: Alpha Lipoic Acid 600 MG Oral Tablet
Normalized name: alpha lipoic acid 600 mg ORAL TABLET
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha Lipoic Acid 600 MG Oral Tablet once daily
Study: NCT05265923
Drug: CM310
Normalized name: Immunoglobulin G4 [227-proline], anti-(human interleukin 4 receptor subunit α) (human-Mus musculus monoclonal CM310 γ4-chain), disulfide with human-Mus musculus monoclonal CM310 κ-chain, dimer
DrugBank: Stapokibart (DB18990)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-4Rα monoclonal antibody
Study: NCT06252103
Drug: Ferrous Gluconate 300 MG
Normalized name: ferrous gluconate 300 MG
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iron salt one tab 300 mg contain 35 mg of elemental iron given 2 doses 600 mg per day
Study: NCT06252103
Drug: ferrous gluconate with lactoferrin
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin is a glycoprotein from the transferrin family consist of 691 amino acids,Lactoferrin is a protein found in cow milk and human milk
Study: NCT05320705
Drug: Intra Operative Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine will be administered as a bolus dose, before the surgical incision with 1mcg/kg iv in 100 ml saline solution over 10 minutes followed by infusion rate of 0.5 μg/kg per h infusion via syringe pump during surgery and stopped at the end of operation. Similar bolus and infusion volumes of normal saline will be administered in the Control group (placebo) However, anaesthesiologists will be permitted to reduce dose of the study drug as necessary to preserve haemodynamic stability.
Study: NCT04507919
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg
Study: NCT04507919
Drug: Trametininb
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.0 mg
Study: NCT06566326
Drug: Propofol and ketamine
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received IV sedation using prepared mixture of propofol and ketamine in ratio (4:1). It is prepared by mixing 0.8 mg/kg propofol with 0.2 mg/kg ketamine (4:1) in an IV bolus, followed by half of the initial dose every 3 minutes as needed for sedation. The desired level of sedation was achieved (more than score 4) using Modified Ramsay sedation score) before allowing endoscopiest to start the procedure, then the score was assessed every 3 minutes before giving of top up doses of ketofol 4:1 (half of the initial dose) if needed, then the range and median of modified Ramsay sedation score was calculated.
Study: NCT06699472
Drug: Trilaciclib Injection [Cosela]
Normalized name: trilaciclib Injection [Cosela]
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilaciclib, intravenous infusion, 240 mg/m2, administered following chemotherapy (2 hours after completion of vincristine administration and within 4 hours before administration of other chemotherapy drugs)
Study: NCT00000672
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06699576
Drug: HS-20093
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-20093: administered as an IV infusion
Study: NCT06699576
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib: 12mg once daily (QD) orally
Study: NCT05063357
Drug: 131I-Omburtamab
Normalized name: 131I-omburtamab
DrugBank: Omburtamab I-131 (DB17124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omburtamab is a murine IgG1 monoclonal antibody, recognizing CD276 (also known as B7-H3).
Study: NCT06699576
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin: administered as an IV infusion
Study: NCT06617949
Drug: Hydromorphone Patient Controlled Analgelsic
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group will be administered epidural PCA as a modality for pain control post cesarian section
Study: NCT05945615
Drug: Oxymetazoline 0.1% (Pf) Oph Soln Ud
Normalized name: OXYMETAZOLINE 0.1% (PF) OPH SOLN UD
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline was initially developed in 1961. It is a direct sympathomimetic, binding directly to alpha-1 and alpha-2 receptors. Currently, it is used as a nasal decongestant, in the treatment of epistaxis, and as a topical treatment for rosacea. Previously, an ophthalmic formulation was used to treat eye redness and irritation as it is FDA approved for the treatment of acquired blepharoptosis. However, this product line was discontinued when in July of 2020, oxymetazoline received Food and Drug Administration approval for treatment of cosmetic blepharoptosis.~In the treatment of blepharoptosis, oxymetazoline acts on the superior tarsal muscle, Müller's muscle, to elevate the eyelid. The superior tarsal muscle is a sympathetically innervated muscle that is partially responsible for elevating the eyelid. Previous cosmetic studies have shown oxymetazoline can serve as an adjunct to botulinum toxin in patients with acquired blepharoptosis.
Study: NCT06699576
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab: administered as an IV infusion
Study: NCT06698484
Drug: CAR-T cells
Normalized name: SynKIR-meso CAR-T cells
DrugBank: SynKIR-110 (DB17365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2×10\^6 CAR T cells/kg
Study: NCT05514405
Drug: Remimazolam (Byfavo)
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam is continuously infused based on bispectral index (within 40-60).
Study: NCT05514405
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol is continuously infused based on bispectral index (within 40-60).
Study: NCT05326347
Drug: OPC-34712FUM/ Brexpiprazole fumarate
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation.
Study: NCT00000753
Drug: Atevirdine mesylate
Normalized name: mesylate
DrugBank: Atevirdine (DB12264)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000753
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000753
Drug: Zalcitabine
Normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000753
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03867487
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
Study: NCT05037123
Drug: Continuous ketamine infusion
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous ketamine infusion (0.35 mg/kg after induction, followed by 0.25 mg/kg/hr until 2 hours after surgery) plus saline IV dose in post-anesthesia care unit
Study: NCT05037123
Drug: Ketamine + Saline
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline dose and infusion intraoperatively, then single-dose IV ketamine (0.60 mg/kg) in post-anesthesia care unit plus 2 hours of saline administration after surgery
Study: NCT00000743
Drug: Alvircept sudotox
Normalized name: Alvircept sudotox
DrugBank: Alvircept sudotox (DB12786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000743
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02229175
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injections of antibodies inhibiting vascular endothelial growth factor
Study: NCT05665075
Drug: QN-023a
Normalized name: QN-302
DrugBank: QN-302 (DB18156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK cell therapy
Study: NCT05665075
Drug: Cyclophosphamid
Normalized name: Cyclophosphamid
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lympho-conditioning Agent
Study: NCT05665075
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lympho-conditioning Agent
Study: NCT05665075
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lympho-conditioning Agent
Study: NCT05665075
Drug: VP-16
Normalized name: Provp-16i
DrugBank: Etoposide toniribate (DB17255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lympho-conditioning Agent
Study: NCT06255392
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib capsules appropriate dose oral, each treatment cycle defined as 3 weeks (21 days).
Study: NCT06255392
Drug: Apatinib Mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib Mesylate oral; each treatment cycle defined as 3 weeks (21 days).
Study: NCT06255392
Drug: Vinorelbine Tartrate Oral
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For the first three courses: reasonable dosage with reference to guidelines. After 3 courses of medication, it is recommended to increase the dose of vinorelbine tartrate once a week. Each treatment cycle defined as 3 weeks (21 days).
Study: NCT06255392
Drug: Eribulin mesylate injection
Normalized name: Eribulin Mesylate Injection
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
Study: NCT06255392
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
Study: NCT06255392
Drug: Paclitaxel-albumin
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-albumin, reasonable dosage with reference to guidelines, each treatment cycle defined as 3 weeks (21 days).
Study: NCT00269802
Drug: OROS methylphenidate HCl
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00269802
Drug: Ritalin
Normalized name: Ritalin
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06627309
Drug: Bortezomib (drug)
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib is administered subcutaneously. The dosage range from 0.7 to 1.3 mg/m2 on days 1, 8, 15, and 22 of each cycle, for a maximum of 6 cycles
Study: NCT06627309
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone is administered intravenously at a dose of 40 mg weekly for each cycle, for a maximum of 6 cycles. For patients over 70 years of age or with severe edema, heart failure, or uncontrolled diabetes mellitus, dexamethasone can be administered at a dose of 10-20 mg per week.
Study: NCT06258720
Drug: Lu AF82422
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AF82422 solution for intravenous infusion
Study: NCT05861128
Drug: Jaktinib
Normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 100 mg Jaktinib orally twice daily for 32 weeks